NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy … (redOrbit)

February 8, 2010 — Jesse

ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.

Read the rest here:
NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy … (redOrbit)

Posted in H3N2 Flu Info, H3N2 Influenza Information. Tags: , , , , , , , , .
«

»